March Biosciences
March Biosciences is a spinoff from the Baylor College of Medicine Cell and Gene Therapy Center with a mission to target challenging hematological cancers not currently addressed by immunotherapy. The lead asset, MB-105, is a CD5-targeted CAR T-cell therapy already in Phase I trials for adults and pediatric patients with treatment refractory T-cell lymphoma and leukemia, rare diseases with an exceptionally poor prognosis. MB-105 has already demonstrated strong safety and efficacy signals in these indications, with multiple patients alive 4 years after treatment. The company is now preparing to advance MB-105 into Phase 2 studies for T-cell lymphoma.
